BASEL, Switzerland, May 12, 2026
Roche announced that it has received European CE Mark approval for Elecsys® plasma phosphorylated-tau 217 (pTau217), a next-generation blood-based diagnostic assay designed to detect Alzheimer’s disease pathology through a routine blood draw. The approval marks a major advancement in the rapidly growing field of neurodegenerative disease diagnostics and positions Roche among the leading companies developing scalable blood-based solutions for earlier and more accessible Alzheimer’s detection. Developed in collaboration with Eli Lilly and Company, the Elecsys® pTau217 assay is designed to help clinicians both rule in and rule out amyloid pathology, one of the central biological hallmarks associated with Alzheimer’s disease. Roche stated that the assay delivers diagnostic performance comparable to established cerebrospinal fluid (CSF) testing and PET imaging while offering a significantly less invasive and more accessible alternative through standard laboratory workflows.
Blood-Based Alzheimer’s Diagnostics Could Accelerate Earlier Detection
The CE Mark approval comes as healthcare systems worldwide continue facing major challenges associated with delayed Alzheimer’s diagnosis and limited access to specialized neurological testing. Roche highlighted that approximately 75% of people living with dementia remain undiagnosed globally, while patients often wait an average of 3.5 years after the onset of cognitive symptoms before receiving a confirmed diagnosis. Alzheimer’s disease represents the most common cause of dementia worldwide, making earlier identification of disease pathology increasingly important as new therapeutic options continue emerging across the neurology sector. Roche stated that the Elecsys® pTau217 assay was specifically developed to simplify and accelerate the diagnostic pathway by enabling healthcare providers to detect Alzheimer’s-related amyloid pathology through a minimally invasive blood test instead of relying primarily on expensive imaging procedures or lumbar puncture-based CSF analysis.
The assay measures phosphorylated tau 217 protein, a recognized biomarker associated with amyloid plaque accumulation in the brain. According to Roche, elevated pTau217 levels indicate a high likelihood of Alzheimer’s-related amyloid pathology and may support earlier specialist referrals, improved patient management, and more timely treatment planning. Conversely, negative test results may help clinicians rule out Alzheimer’s disease and redirect diagnostic efforts toward alternative neurological or cognitive conditions. Roche emphasized that the same clinical cutoff values can be applied across both primary care and specialist healthcare environments, allowing for broader deployment and more standardized interpretation across different clinical settings.
Clinical Data Demonstrates Accuracy Comparable to PET Imaging
Advertisement
Roche reported that the CE Mark authorization was supported by retrospective studies involving patients at the earliest symptomatic stages of Alzheimer’s disease, including individuals with subjective cognitive decline, mild cognitive impairment, and mild dementia. The company stated that the assay demonstrated strong agreement with amyloid PET imaging, which remains the gold standard for confirming amyloid pathology in Alzheimer’s disease. By maintaining high diagnostic accuracy while utilizing a simple blood sample, Roche believes the assay could significantly improve testing accessibility and reduce healthcare system burdens associated with specialized neurological diagnostics..
Importantly, the Elecsys® pTau217 assay was developed for integration into Roche’s existing global installed base of automated diagnostic instruments, enabling high-throughput implementation across routine laboratory settings. Roche noted that this scalability could help accelerate adoption throughout countries recognizing CE Mark approvals while supporting broader population-level screening and earlier disease identification initiatives. The company also confirmed plans to pursue U.S. regulatory approval later in 2026 through the FDA review pathway, potentially expanding access to the assay across the American healthcare market.
Roche Expands Alzheimer’s Portfolio Across Diagnostics and Therapeutics
The Elecsys® pTau217 approval further strengthens Roche’s broader Alzheimer’s disease strategy spanning diagnostics, therapeutics, and digital health technologies. In addition to its expanding biomarker testing portfolio, Roche continues advancing investigational Alzheimer’s therapies targeting multiple disease mechanisms and stages of progression. The company’s neurology pipeline currently includes trontinemab, an investigational amyloid-beta targeting monoclonal antibody engineered for enhanced brain penetration, as well as nivegacetor, an oral gamma-secretase modulator designed to reduce amyloid plaque formation. Roche executives stated that expanding access to accurate blood-based biomarker testing could play a transformative role in improving patient identification for future disease-modifying Alzheimer’s therapies while enabling earlier intervention strategies designed to preserve cognitive function and quality of life.
Roche added that continued collaboration between diagnostic developers, healthcare systems, clinicians, regulators, and patient advocacy groups will remain essential to addressing the growing global burden of Alzheimer’s disease and dementia-related disorders.
Source: Roche press release
